Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist (cetrorelix) on ovarian hyperstimulation in lower-weight Asian women.

Chang YL, Hsieh YY, Tsai HD

Taiwanese journal of obstetrics & gynecology1 Dec 2006Cited by 8 (Europe PMC)

PMID17175489DOI10.1016/s1028-4559(09)60250-3PepBankPUB-17175489

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, clinical pregnancy rates were higher with cetrorelix 0.2 mg/day than 0.15 mg/day: 28.6% versus 20%.
In plain wordsIn lower-weight Asian women, pregnancy rates were 28.6% with cetrorelix 0.2 mg/day versus 20% with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
IncreaseClinical pregnancy rate
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Clinical pregnancy rate
28.6%
0.2 mg/day
Clinical pregnancy rate
20%
0.15 mg/day
Source sentences
Summary
The clinical pregnancy/implantation rates in Group 1 were higher than those in Group 2 (28.6%/10.4% vs. 20%/4.1%).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548901
02HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, implantation rates were higher with cetrorelix 0.2 mg/day than 0.15 mg/day: 10.4% versus 4.1%.
In plain wordsIn lower-weight Asian women, implantation rates were 10.4% with cetrorelix 0.2 mg/day versus 4.1% with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
IncreaseImplantation rate
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Implantation rate
10.4%
0.2 mg/day
Implantation rate
4.1%
0.15 mg/day
Source sentences
Summary
The clinical pregnancy/implantation rates in Group 1 were higher than those in Group 2 (28.6%/10.4% vs. 20%/4.1%).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548902
03HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, retrieved oocyte numbers were higher with cetrorelix 0.2 mg/day than 0.15 mg/day: 10.5 versus 8.3.
In plain wordsIn lower-weight Asian women, cetrorelix 0.2 mg/day yielded 10.5 oocytes versus 8.3 with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
IncreaseRetrieved oocytes
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Retrieved oocytes
10.5 oocytes
0.2 mg/day
Retrieved oocytes
8.3 oocytes
0.15 mg/day
Source sentences
Summary
The numbers of oocytes retrieved/Grade I-II embryos were higher in Group 1 than Group 2 (10.5/7.8 vs. 8.3/3.9).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548903
04HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, Grade I-II embryo numbers were higher with cetrorelix 0.2 mg/day than 0.15 mg/day: 7.8 versus 3.9.
In plain wordsIn lower-weight Asian women, cetrorelix 0.2 mg/day yielded 7.8 Grade I-II embryos versus 3.9 with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
IncreaseGrade I-II embryos
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Grade I-II embryos
7.8 embryos
0.2 mg/day
Grade I-II embryos
3.9 embryos
0.15 mg/day
Source sentences
Summary
The numbers of oocytes retrieved/Grade I-II embryos were higher in Group 1 than Group 2 (10.5/7.8 vs. 8.3/3.9).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548904
05HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, LH surge occurred less often with cetrorelix 0.2 mg/day than 0.15 mg/day: 5.9% versus 26.7%.
In plain wordsIn lower-weight Asian women, LH surges occurred in 5.9% with cetrorelix 0.2 mg/day versus 26.7% with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
DecreaseLH surge
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
LH surge
5.9%
0.2 mg/day
LH surge
26.7%
0.15 mg/day
Source sentences
Summary
A lower percentage of LH surge and higher E2 levels on the day of hCG administration were observed in Group 1 compared to Group 2 (5.9%/1,610.8 pg/mL vs. 26.7%/1,023.6 pg/mL).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548905
06HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, estradiol was higher with cetrorelix 0.2 mg/day than 0.15 mg/day: 1,610.8 versus 1,023.6 pg/mL.
In plain wordsIn lower-weight Asian women, estradiol was 1,610.8 pg/mL with cetrorelix 0.2 mg/day versus 1,023.6 pg/mL with 0.15 mg/day.
Peptide
Cetrorelix
Outcome
IncreaseEstradiol on hCG day
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1610.8 pg/mL
0.2 mg/day
Estradiol
1023.6 pg/mL
0.15 mg/day
Source sentences
Summary
A lower percentage of LH surge and higher E2 levels on the day of hCG administration were observed in Group 1 compared to Group 2 (5.9%/1,610.8 pg/mL vs. 26.7%/1,023.6 pg/mL).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548906
07HumanRandomized controlled trialEfficacy outcome
In lower-weight Asian women, gonadotropin dosage did not differ significantly between cetrorelix 0.2 and 0.15 mg/day.
In plain wordsIn lower-weight Asian women, gonadotropin doses did not differ significantly between cetrorelix 0.2 and 0.15 mg/day.
Peptide
Cetrorelix
Outcome
No significant changeGonadotropin dosage
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
There were no statistical differences between the two groups when comparing gonadotropin dosage and OHSS.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548907
08HumanRandomized controlled trialSafety outcome
In lower-weight Asian women, OHSS did not differ significantly between cetrorelix 0.2 and 0.15 mg/day.
In plain wordsIn lower-weight Asian women, ovarian hyperstimulation syndrome did not differ significantly between cetrorelix 0.2 and 0.15 mg/day.
Peptide
Cetrorelix
Outcome
No significant changeOHSS
Study
n = 58
Comparator
Cetrorelix 0.15 mg/day
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mg/day · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
There were no statistical differences between the two groups when comparing gonadotropin dosage and OHSS.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized controlled trial of GnRH antagonist was performed.
Summary · context
A total of 58 women with body weight of 40-50 kg accepted COH and transvaginal embryo transfer.
Summary · context
Patients were divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2 patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day.
Summary · context
Cetrorelix was administered from menstrual day 8 until the day of human chorionic gonadotropin (hCG) administration.
Report a problemFND-1717548908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.